Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...
On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...